Chemistry-to-gene screens in Caenorhabditis elegans

Nature Reviews Drug Discovery

Volumn 4, Issue 4, 2005, Pages 321-330

  Jones, Andrew K ^a   Buckingham, Steven D ^a   Sattelle, David B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALDICARB; ANESTHETIC AGENT; ANTIPARASITIC AGENT; BENZIMIDAZOLE DERIVATIVE; DNA MARKER; GENE PRODUCT; INHALATION ANESTHETIC AGENT; IVERMECTIN; LEVAMISOLE; NEW DRUG; NICOTINE; ANTINEMATODAL AGENT;

CAENORHABDITIS ELEGANS; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENE MUTATION; GENETIC MODEL; GENETIC SCREENING; GENOME; NONHUMAN; PARASITOSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANIMAL; ANIMAL MODEL; CHEMISTRY; DRUG DESIGN; DRUG RESISTANCE; GENE; GENETICS; GROWTH, DEVELOPMENT AND AGING;

ANIMALS; ANTINEMATODAL AGENTS; CAENORHABDITIS ELEGANS; DRUG DESIGN; DRUG RESISTANCE; GENES, HELMINTH; MODELS, ANIMAL;

EID: 18244371439     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1692     Document Type: Review

References (114)

1. Chan, M. S. The global burden of intestinal nematode infections - fifty years on. Parasitol. Today 13, 438-443 (1997).
2. Jasmer, D. P., Goverse, A. & Smant, G. Parasitic nematode interactions with mammals and plants. Annu. Rev. Phytopathol. 41, 245-270 (2003).
3. Kaplan, R. M. Drug resistance in nematodes of veterinary importance: a status report. Trends Parasitol. 20, 477-481 (2004).
4. Geary, T. G. & Thomson, D. P. Caenorhabditis elegans: how good a model for veterinary parasites? Vet. Parasitol. 101, 371-386 (2001).
5. Ankeny, R. A. The natural history of Caenorhabditis elegans research. Nature Rev. Genet. 2, 474-479 (2001).
6. Sulston, J. E. & Horvitz, H. R. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev. Biol. 56, 110-156 (1977).
7. White, J. G., Southgate, E., Thomson, J. N. & Brenner, S. The structure of the ventral nerve cord of Caenorhabditis elegans. Philos. Trans. R. Soc. Lond. B Biol. Sci. 275, 327-348 (1976).
8. Genome sequence of the nematode C. elegans: a platform for investigating biology. The C. elegans Sequencing Consortium. Science 262, 2012-2018 (1998).
9. Harris, T. W. et al. WormBase: a multi-species resource for nematode biology and genomics. Nucleic Acids Res. 32, D411-D417 (2004).
10. Jorgensen, E. M. & Mango, S. E. The art and design of genetic screens: Caenorhabditis elegans. Nature Rev. Genet. 3, 356-369 (2002).
11. Carpenter, A. E. & Sabatini, D. M. Systematic genome-wide screens of gene function. Nature Rev. Genet. 5, 11-22 (2004).
12. Sulston, J. E. Caenorhabditis elegans: the cell lineage and beyond (Nobel lecture). Chembiochem 4, 688-696 (2003).
13. Chalfie, M. & Jorgensen, E. M. C. elegans neuroscience: genetics to genome. Trends Genet. 14, 506-512 (1998).
14. Baehrecke, E. H. How death shapes life during development. Nature Rev. Mol. Cell Biol. 3, 779-787 (2002).
15. Culetto, E. & Sattelle, D. B. A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum. Mol. Genet. 9, 869-877 (2000).
16. Driscoll, M. & Gerstbrein, B. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nature Rev. Genet. 4, 181-194 (2003).
17. Poulin, G., Nandakumar, R. & Ahringer, J. Genome-wide RNAi screens in Caenorhabditis elegans: impact on cancer research. Oncogene 23, 8340-8345 (2004).
18. Raymond, V. & Sattelle, D. B. Novel animal-health drug targets from ligand-gated chloride channels. Nature Rev. Drug Discov. 1, 427-436 (2002).
19. Chen, N. et al. WormBase: a comprehensive data resource for Caenorhabditis biology and genomics. Nucleic Acids Res. 33, D383-D389 (2005).
20. Brenner, S. The genetics of Caenorhabditis elegans. Genetics 77, 71-94 (1974).
21. Jakubowski, J. & Kornfeld, K. A local, high-density, single-nucleotide polymorphism map used to clone Caenorhabditis elegans cdf-1. Genetics 153, 743-752 (1999).
22. Bessereau, J. L. et al. Mobilization of a Drosophila transposon in the Caenorhabditis elegans germ line. Nature 413, 70-74 (2001).
23. Martin, E. et al. Identification of 1088 new transposon insertions of Caenorhabditis elegans: a pilot study toward large-scale screens. Genetics 162, 521-524 (2002).
24. Thienpont, D. et al. Tetramisole (R 8299), a new, potent broad spectrum anthelmintic. Nature 209, 1084-1086 (1966).
25. Lewis, J. A., Wu, C. H., Levine, J. H. & Berg, H. Levamisole-resistant mutants of the nematode Caenorhabditis elegans appear to lack pharmacological acetylcholine receptors. Neuroscience 5, 967-989 (1980).
26. Harrow, I. D. & Gration, K. A. F. Mode of action of the anthelmintics morantel, pyrantel and levamisole on muscle cell membrane of the nematode Ascaris suum. Pestic. Sci. 16, 662-672 (1985).
27. Martin, R. J., Valkanov, M. A., Dale, V. M., Robertson, A. P. & Murray, I. Electrophysiology of Ascaris muscle and anti-nematodal drug action. Parasitology 113, S137-S156 (1996).
28. Lewis, J. A. et al. Cholinergic receptor mutants of the nematode Caenorhabditis elegans. J. Neurosci. 7, 3059-3071 (1987).
29. Fleming, J. T. et al. Caenorhabditis elegans levamisole resistance genes lev-1, unc-29, and unc-38 encode functional acetylcholine receptor subunits. J. Neurosci. 15, 5843-5857 (1997).
30. Culetto, E. et al. The Caenorhabditis elegans unc-63 gene encodes a levamisole-sensitive nicotinic acetylcholine receptor α subunit. J. Biol. Chem. 279, 42476-42483 (2004).
31. Towers, P. R. & Sattelle, D. B. The C. elegans lev-8 gene encodes a nicotinic acetylcholine receptor subunit (ACR-13) with roles in egg laying and pharyngeal pumping. J. Neurochem. 93, 1-9 (2005).
32. Karlin, A. Emerging structure of the nicotinic acetylcholine receptors. Nature Rev. Neurosci. 3, 102-114 (2002).
33. Jones, A. K. & Sattelle, D. B. Functional genomics of the nicotinic acetylcholine receptor gene family of the nematode, Caenorhabditis elegans. Bioessays 26, 39-49 (2004).
34. Richmond, J. E. & Jorgensen, E. M. One GABA and two acetylcholine receptors function at the C. elegans neuromuscular junction. Nature Neurosci. 2, 791-797 (1999).
35. Robertson, A. P., Bjorn, H. E. & Martin, R. J. Resistance to levamisole resolved at the single-channel level. FASEB J. 13, 749-760 (1999).
36. Robertson, A. P., Bjorn, H. E. & Martin, R. J. Pyrantel resistance alters nematode nicotinic acetylcholine receptor single-channel properties. Eur. J. Pharmacol. 394, 1-8 (2000).
37. Fitzgerald, J. et al. UNCL, the mammalian homologue of UNC-50, is an inner nuclear membrane RNA-binding protein. Brain Res. 877, 110-123 (2000).
38. Gally, C., Eimer, S., Richmond, J. E. & Bessereau, J. L. A transmembrane protein required for acetylcholine receptor clustering in Caenorhabditis elegans. Nature 431, 578-582 (2004).
39. Maryon, E. B., Coronado, R. & Anderson, P. unc-68 encodes a ryanodine receptor involved in regulating C. elegans body-wall muscle contraction. J. Cell. Biol. 134, 885-893 (1996).
40. Jenden, D. J. & Fairhurst, A. S. The pharmacology of ryanodine. Pharmacol. Rev. 21, 1-25 (1969).
41. Benian, G. M., L'Hernault, S. W. & Morris, M. E. Additional sequence complexity in the muscle gene, unc-22, and its encoded protein, twitchin, of Caenorhabditis elegans. Genetics 134, 1097-1104 (1993).
42. Kagawa, H., Takuwa, K. & Sakube, Y. Mutations and expressions of the tropomyosin gene and the troponin C gene of Caenorhabditis elegans. Cell Struct. Funct 22, 213-218 (1997).
43. Nguyen, M., Alfonso, A., Johnson, C. D. & Rand, J. B. Caenorhabditis elegans mutants resistant to inhibitors of acetylcholinesterase. Genetics 140, 527-535 (1995).
44. Miller, K. G. et al. A genetic selection for Caenorhabditis elegans synaptic transmission mutants. Proc. Natl Acad. Sci. USA 93, 12593-12598 (1996).
45. Alfonso, A., Grundahl, K., McManus, J. R. & Rand, J. B. Cloning and characterization of the choline acetyltransferase structural gene (cha-1) from C. elegans. J. Neurosci. 14, 2290-2300 (1994).
46. Alfonso, A., Grundahl, K., Duerr, J. S., Han, H. P. & Rand, J. B. The Caenorhabditis elegans unc-17 gene: a putative vesicular acetylcholine transporter. Science 261, 617-619 (1993).
47. Nonet, M. L., Grundahl, K., Meyer, B. J. & Rand, J. B. Synaptic function is impaired but not eliminated in C. elegans mutants lacking synaptotagmin. Cell 73, 1291-1305 (1993).
48. Maruyama, H., Rakow, T. L. & Maruyama, I. N. Synaptic exocytosis and nervous system development impaired in Caenorhabditis elegans unc-13 mutants. Neuroscience 104, 287-297 (2001).
49. Harada, S., Hori, I., Yamamoto, H. & Hosono, R. Mutations in the unc-41 gene cause elevation of acetylcholine levels. J. Neurochem. 63, 439-446 (1994).
50. Halevi, S. et al. The C. elegans ric-3 gene is required for maturation of nicotinic acetylcholine receptors. EMBO J. 21, 1012-1020 (2002).
51. Campbell, W. C. Benzimidazoles: veterinary uses. Parasitol. Today 6, 130-133 (1990).
52. Cook, G. C. Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy. Parasitol. Today 6, 133-136 (1990).
53. Lacey, E. Mode of action of benzimidazoles. Parasitol. Today 6, 112-115 (1990).
54. Driscoll, M., Dean, E., Reilly, E., Bergholz, E. & Chalfie, M. Genetic and molecular analysis of a Caenorhabditis elegans β-tubulin that conveys benzimidazole sensitivity. J. Cell. Biol. 109, 2993-3003 (1989).
55. Roos, M. H. et al. Molecular analysis of selection for benzimidazole resistance in the sheep parasite Haemonchus contortus. Mol. Biochem. Parasitol. 43, 77-88 (1990).
56. Lubega, G. W., Klein, R. D., Geary, T. G. & Prichard, R. K. Haemonchus contortus: the role of two β-tubulin gene subfamilies in the resistance to benzimidazole anthelmintics. Biochem. Pharmacol. 47, 1705-1715 (1994).
57. Kwa, M. S., Veenstra, J. G. & Roos, M. H. Benzimidazole resistance in Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in β-tubulin isotype 1. Mol. Biochem. Parasitol. 63, 299-303 (1994).
58. Kwa, M. S., Veenstra, J. G., Van Dijk, M. & Roos, M. H. β-tubulin genes from the parasitic nematode Haemonchus contortus modulate drug resistance in Caenorhabditis elegans. J. Mol. Biol. 246, 500-510 (1995).
59. Omura, S. & Crump, A. The life and times of ivermectin - a success story. Nature Rev. Microbiol. 2, 984-989 (2004).
60. Remme, J. H. Research for control: the onchocerciasis experience. Trop. Med. Int. Health. 9, 243-254 (2004).
61. Fritz, L. C., Wang, C. C. & Gorio, A. Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance. Proc. Natl Acad. Sci. USA 76, 2062-2066 (1979).
62. Duce, I. R. & Scott, R. H. Actions of dihydroavermectin B1a on insect muscle. Br. J. Pharmacol. 85, 395-401 (1985).
63. Cully, D. F. et al. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 371, 707-711 (1994).
64. Vassilatis, D. K. et al. Genetic and biochemical evidence for a novel avermectin-sensitive chloride channel in Caenorhabditis elegans. Isolation and characterization. J. Biol. Chem. 272, 33167-33174 (1997).
65. Yates, D. M., Portillo, V. & Wolstenholme, A. J. The avermectin receptors of Haemonchus contortus and Caenorhabditis elegans. Int. J. Parasitol. 33, 1183-1193 (2003).
66. Dent, J. A., Davis, M. W. & Avery, L. avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. EMBO J. 16, 5867-5879 (1997).
67. Dent, J. A., Smith, M. M., Vassilatis, D. K. & Avery, L. The genetics of ivermectin resistance in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 97, 2674-2679 (2000).
68. Flores, C. M., Rogers. S. W., Pabreza, L. A., Wolfe, B. B. & Kellar, K. J. A subtype of nicotinic cholinergic receptor in rat brain is composed of α4 and β2 subunits and is up-regulated by chronic nicotine treatment. Mol. Pharmacol. 41, 31-37 (1992).
69. Molinari, E. J. et al. Up-regulation of human α7 nicotinic receptors by chronic treatment with activator and antagonist ligands. Eur. J. Pharmacol. 347, 131-139 (1998).
70. Waggoner, L. E. et al. Long-term nicotine adaptation in Caenorhabditis elegans involves PKC-dependent changes in nicotinic receptor abundance. J. Neurosci. 20, 8802-8811 (2000).
71. Davies, A. G. et al. A central role of the BK potassium channel in behavioral responses to ethanol in C. elegans. Cell 115, 655-666 (2003).
72. Wang, Z. W., Saifee, O., Nonet, M. L. & Salkoff, L. SLO-1 potassium channels control quantal content of neurotransmitter release at the C. elegans neuromuscular junction. Neuron 32, 867-881 (2001).
73. Saifee, O., Wei, L. & Nonet, M. L. The Caenorhabditis elegans unc-64 locus encodes a syntaxin that interacts genetically with synaptobrevin. Mol. Biol. Cell 9, 1235-1252 (1998).
74. Wang, Z. W., Saifee, O., Nonet, M. L. & Salkoff, L. A neomorphic syntaxin mutation blocks volatile-anesthetic action in Caenorhabditis elegans. Neuron 96, 867-881 (1999).
75. Hawasli, A. H., Saifee, O., Liu, C., Nonet, M. L. & Crowder, C. M. Resistance to volatile anesthetics by mutations enhancing excitatory neurotransmitter release in Caenorhabditis elegans. Genetics 168, 831-843 (2004).
76. Lackner, M. R., Nurrish, S. J. & Kaplan, J. M. Facilitation of synaptic transmission by EGL-30 Gqα and EGL-8 PLCβ: DAG binding to UNC-13 is required to stimulate acetylcholine release. Neuron 24, 335-346 (1999).
77. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
78. Timmons, L. & Fire, A. Specific interference by ingested dsRNA. Nature 395, 854 (1998).
79. Tabara, H., Grishok, A. & Mello, C. C. RNAi in C. elegans: soaking in the genome sequence. Science 282, 430-431 (1998).
80. Kamath, R. S. et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421, 231-237 (2003).
81. Ashrafi, K. et al. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421, 268-272 (2003).
82. Colaiacovo, M. P. et al. A targeted RNAi screen for genes involved in chromosome morphogenesis and nuclear organization in the Caenorhabditis elegans germline. Genetics 162, 113-128 (2002).
83. Lee, S. S. et al. A systematic RNAi screen identifies a critical role for mitochondria in C. elegans longevity. Nature Genet. 33, 40-48 (2003).
84. Poulin, G., Nandakumar, R. & Ahringer, J. Genome-wide RNAi screens in Caenorhabditis elegans: impact on cancer research. Oncogene 23, 8340-8345 (2004).
85. Buckingham, S. D., Esmaeili, B., Wood, M. & Sattelle, D. B. RNA interference: from model organisms towards therapy for neural and neuromuscular disorders. Hum. Mol. Genet. 13, R275-R288 (2004).
86. Simmer, F. et al. Loss of the putative RNA-directed RNA polymerase RRF-3 makes C. elegans hypersensitive to RNAi. Curr. Biol. 12, 1317-1319 (2002).
87. Kennedy, S., Wang, D. & Ruvkun, G. A conserved siRNA-degrading RNase negatively regulates RNA interference in C. elegans. Nature 427, 645-649 (2004).
88. Simmer, F. et al. Genome-wide RNAi of C. elegans using the hypersensitive rrf-3 strain reveals novel gene functions. PLoS Biol. 1, E12 (2003).
89. Appleford, P. J. et al. Functional redundancy of two nucleoside transporters of the ENT family (CeENT1, CeENT2) required for development of Caenorhabditis elegans. Mol. Membr. Biol. 21, 247-259 (2004).
90. Li, S. et al. A map of the interactome network of the metazoan C. elegans. Science 303, 540-543 (2004).
91. Rual, J. F. et al. Toward improving Caenorhabditis elegans phenome mapping with an ORFeome-based RNA library. Genome Res. 14, 2162-2168 (2004).
92. Gaud, A. et al. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul. Disord. 14, 365-370 (2004).
93. Ahn, A. H. & Kunkel, L. M. The structural and functional diversity of dystrophin. Nature Genet. 3, 283-291 (1993).
94. Gieseler, K., Grisoni, K. & Segalat, L. Genetic suppression of phenotypes arising from mutations in dystrophin-related genes in Caenorhabditis elegans. Curr. Biol. 10, 1092-1097 (2000).
95. Melov, S. et al. Extension of life-span with superoxide dismutase/catalase mimetics. Science 289, 1567-1569 (2000).
96. Rong, Y., Doctrow, S. R., Tocco, G. & Baudry M. EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology. Proc. Natl Acad. Sci. USA 96, 9897-9902 (1999).
97. Jung, C. et al. Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett. 304, 157-160 (2001).
98. Link, C. D. Expression of human β-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 92, 9368-9372 (1995).
99. Parkinson, J. et al. A transcriptomic analysis of the phylum Nematoda. Nature Genet. 36, 1250-1267 (2004).
100. Ghedin, E., Wang, S., Foster, J. M. & Slatko, B. E. First sequenced genome of a parasitic nematode. Trends Parasitol. 20, 151-153 (2004).
101. Reynolds, N. K., Schade, M. A. & Miller, K. Convergent, RIC-8 dependent Gα signaling pathways in the C. elegans synaptic signaling network. Genetics 169, 651-670 (2005).
102. Doi, M. & Iwasaki, K. Regulation of retrograde signaling at neuromuscular junctions by the novel C2 domain protein AEX-1. Neuron 33, 249-259 (2002).
103. Patikoglou, G. A. & Koelle, M. R. An N-terminal region of Caenorhabditis elegans RGS proteins EGL-10 and EAT-16 directs inhibition of Gαo versus Gαq signaling. J. Biol. Chem. 277, 47004-47013 (2002).
104. Bastiani, C. A., Gharib, S., Simon, M. I. & Sternberg, P. W. Caenorhabditis elegans Gαq regulates egg-laying behavior via a PLCβ-independent and serotonin-dependent signaling pathway and likely functions both in the nervous system and in muscle. Genetics 165, 1805-1822 (2003).
105. Schafer, W. R. & Kenyon, C. J. A calcium-channel homologue required for adaptation to dopamine and serotonin in Caenorhabditis elegans. Nature 375, 73-78 (1995).
106. Koushika, S. P. et al. A post-docking role for active zone protein Rim. Nature Neurosci. 4, 997-1005 (2001).
107. Grunwald, M. E., Mellem, J. E., Strutz, N., Maricq, A. V. & Kaplan, J. M. Clathrin-mediated endocytosis is required for compensatory regulation of GLR-1 glutamate receptors after activity blockade. Proc. Natl Acad. Sci. USA 101, 3190-3195 (2004).
108. Weimer, R. M. et al. Defects in synaptic vesicle docking in unc-18 mutants. Nature Neurosci. 6, 1023-1030 (2003).
109. Harris, T. W., Hartwieg, E., Horvitz, H. R. & Jorgensen, E. M. Mutations in synaptojanin disrupt synaptic vesicle recycling. J. Cell. Biol. 150, 589-600 (2000).
110. Berwin, B., Floor, E. & Martin, T. F. CAPS (mammalian UNC-31) protein localizes to membranes involved in dense-core vesicle exocytosis. Neuron 21, 137-145 (1998).
111. Pujol, N., Bonnerot, C., Ewbank, J. J., Kohara, Y. & Thierry-Mieg, D. The Caenorhabditis elegans unc-32 gene encodes alternative forms of a vacuolar ATPase α subunit. J. Biol. Chem. 276, 11913-11921 (2001).
112. Schafer, W. R., Sanchez, B. M. & Kenyon, C. J. Genes affecting sensitivity to serotonin in Caenorhabditis elegans. Genetics 143, 1219-1230 (1996).
113. Loria, P. M., Duke, A., Rand, J. B. & Hobert, O. Two neuronal, nuclear-localized RNA binding proteins involved in synaptic transmission. Curr. Biol. 13, 1317-1323 (2003).
114. Hall, D. H. & Hedgecock, E. M. Kinesin-related gene unc-104 is required for axonal transport of synaptic vesicles in C. elegans. Cell 65, 837-847 (1991).